---
title: BIOSECURE Act CDMO supply chain risk: 5-10% annual capacity tightening
slug: biosecure-act-cdmo-supply-chain-risk-5-10-annual-capacity-tightening-cdmo
site: cdmo
post_kind: deep_dive
byline: Carlton Hoyt
description: Modern Catalyst The BIOSECURE Act has fundamentally reshaped the CDMO vendor landscape in ways that extend far beyond compliance checkboxes. Rather than a one-time regulatory adjustment, the Act is…
canonical_url: https://cdmo.directory/posts/biosecure-act-cdmo-supply-chain-risk-5-10-annual-capacity-tightening-cdmo
published_at: 2026-07-16T05:00:57.158Z
last_updated: 2026-07-16T05:00:57.169Z
---

## Modern Catalyst

The BIOSECURE Act has fundamentally reshaped the CDMO vendor landscape in ways that extend far beyond compliance checkboxes. Rather than a one-time regulatory adjustment, the Act is triggering a structural capacity contraction that will persist through 2026 and beyond—one that procurement teams cannot simply absorb through negotiation alone.

The core mechanism is straightforward but consequential: any pharmaceutical product manufactured by a [Biotechnology Company of Concern](https://www.mofo.com/resources/insights/251218-biosecure-act-update) becomes ineligible for sale to the U.S. market. This definition captures not only Chinese-headquartered firms but also any CDMO with material ownership, control, or supply-chain dependencies rooted in China. The OMB is expected to publish the formal list of restricted entities in late 2026, but the uncertainty window is already forcing decisions.

[CDMO rates are expected to rise 5–10% annually](https://visionlifesciences.com/insights/biosecure-act-pharma-impact-2026) as capacity tightens. This is not a temporary price spike; it reflects genuine scarcity. Sponsors are simultaneously de-risking their supply chains and competing for the same pool of compliant manufacturing slots. The vendors who can credibly demonstrate zero exposure to restricted entities—whether through ownership, raw-material sourcing, or subcontractor networks—command premium pricing and priority allocation.

Equally significant is the shift in how supply-chain risk is now mapped. The [BIOSECURE Act has moved China](https://www.outsourcedpharma.com/doc/biosecure-act-and-the-supply-chain-lessons-sponsors-can-t-ignore-0001) exposure from a vendor-management issue to a network-mapping exercise. A CDMO may itself be compliant, but if its excipient suppliers, analytical laboratories, or data-processing partners have restricted ties, the entire product line becomes vulnerable. This hidden-node problem is forcing sponsors to conduct forensic audits of their entire manufacturing ecosystem—a process that consumes procurement bandwidth and often reveals uncomfortable dependencies.

The competitive response is already visible. Insilico Medicine and Taiwan-based CDMO Bora Pharmaceuticals are launching a new company with [an AI-driven biologics manufacturing platform](https://endpoints.news/insilico-bora-pharma-reveal-plans-for-ai-driven-manufacturing-company/) to compete with service providers headquartered in China. This signals that non-Chinese, BIOSECURE-compliant capacity is being actively built—but the lead time for new manufacturing facilities is 18–36 months. The gap between current demand and available compliant capacity will remain acute through 2025 and into 2026.

## Structural Impact

The BIOSECURE Act is reshaping vendor selection criteria in three concrete ways that procurement teams must operationalize immediately.

**Capacity allocation and pricing power.** The 5–10% annual rate increase reflects not just inflation or labor costs; it reflects scarcity rent. Sponsors who have not yet locked in CDMO partnerships are entering a buyer's market in reverse. Companies that lock in alternative CDMO partnerships now—before the OMB list is published in [late 2026—will secure better pricing](https://visionlifesciences.com/insights/biosecure-act-pharma-impact-2026) and priority access to capacity. This creates a first-mover advantage with a hard deadline. After the OMB list drops, any sponsor still shopping for manufacturing capacity will face both higher prices and longer lead times. The procurement implication is stark: delay is now a cost multiplier.

**Supply-chain re-engineering and regulatory revalidation.** Many sponsors have built their manufacturing strategies around cost-optimized global networks that now carry BIOSECURE risk. The new Act could compel [substantial supply chain re-engineering, technology](https://www.osborneclarke.com/insights/us-biosecure-act-your-supply-chain-risk) transfers and regulatory revalidations, potentially leading to increased costs, delays and drug supply disruptions. A sponsor may need to transfer manufacturing know-how to a new, compliant CDMO—a process that requires FDA pre-approval inspection, stability data re-generation, and often 12–18 months of parallel manufacturing. These hidden costs are frequently underestimated in initial BIOSECURE impact assessments.

**Compliance auditing as a procurement function.** For life sciences and pharma companies, this necessitates a rigorous audit of Contract Research Organizations (CROs) and [Contract Development and Manufacturing Organizations](https://app.scientist.com/blog/2026/01/20/the-biosecure-act-navigating-changes-in-the-biopharma-supply-chain) (CDMOs) to ensure long-term compliance and mitigate the risk of losing access to the U.S. Procurement teams can no longer rely on vendor attestations alone. Effective due diligence now requires ownership-structure verification, subcontractor mapping, and supply-chain traceability for critical inputs. This is a shift from transactional vendor management to network-level risk governance. Sponsors without dedicated supply-chain intelligence resources are at a disadvantage.

The vendor landscape itself is bifurcating. Established, Western-headquartered CDMOs (Lonza, Catalent, Fujifilm Diosynth, Recro Pharma) are raising prices and extending lead times because demand exceeds capacity. Smaller, regional CDMOs in India, South Korea, and Singapore are gaining traction—but only if they can credibly document zero exposure to restricted entities. This creates an opportunity for procurement teams to negotiate with emerging vendors, but it also increases operational risk if those vendors lack the regulatory maturity or quality infrastructure of tier-one providers.

## Strategic Blueprint

Procurement teams should operationalize BIOSECURE compliance through a phased, network-level approach.

**Phase 1: Immediate audit (Q1–Q2 2025).** Conduct a forensic supply-chain map for all active manufacturing programs. This goes beyond the CDMO contract; it includes excipient suppliers, analytical testing labs, data-processing vendors, and any subcontractors. For each node, document ownership structure, geographic footprint, and any material ties to China. Flag any program where the supply chain is opaque or where a critical input comes from a restricted vendor. This audit should be cross-functional (quality, regulatory, supply-chain, legal) and should produce a risk register with clear remediation timelines.

**Phase 2: Partnership lock-in (Q2–Q3 2025).** For programs flagged as high-risk, initiate negotiations with compliant CDMOs now. The pricing advantage of early commitment is real and quantifiable. Request long-term capacity reservations (3–5 years) with price-escalation caps tied to inflation, not to BIOSECURE-driven scarcity. Negotiate technology-transfer timelines and regulatory-approval pathways upfront. For programs with lower risk, establish contingency partnerships with secondary CDMOs to reduce single-vendor exposure.

**Phase 3: Regulatory pathway planning (Q3–Q4 2025).** Work with regulatory affairs to map the approval pathway for any manufacturing transfer. This includes pre-approval inspections, stability-protocol amendments, and CMC (Chemistry, Manufacturing, and Controls) supplemental filings. Build these timelines into procurement contracts; delays in regulatory approval should not trigger penalty clauses on the CDMO side. Establish clear milestones and decision gates so that procurement can escalate delays early.

**Phase 4: Post-OMB list integration (Q4 2025–Q1 2026).** Once the OMB publishes the formal list of restricted entities, conduct a final compliance audit. Any vendor on the list must be de-risked within 12 months. For programs where no compliant alternative exists, escalate to executive leadership and regulatory affairs immediately; product discontinuation or market-access loss may be unavoidable, but early visibility allows for mitigation planning.

**Vendor selection criteria for 2025–2026.** Procurement should weight BIOSECURE compliance as a primary criterion, not a secondary one. When evaluating new CDMOs, require:

- Audited ownership documentation (no hidden Chinese investment or control)
- Subcontractor and supply-chain mapping (excipients, testing, data services)
- Regulatory history (FDA warning letters, GMP compliance record)
- Capacity availability and lead-time transparency
- Price stability commitments (not just base rates, but escalation clauses)

Emerging vendors in India and Southeast Asia may offer cost advantages, but only if they can provide equivalent compliance documentation and regulatory maturity. Do not assume that a lower-cost CDMO is automatically higher-risk; instead, conduct equivalent due diligence and price the compliance risk into the contract.

**Cross-functional governance.** Establish a BIOSECURE steering committee with representatives from procurement, quality, regulatory, supply-chain, and legal. This committee should meet quarterly to review compliance status, flag emerging risks, and approve any new vendor partnerships. Procurement should not be the sole decision-maker; BIOSECURE compliance is a business-continuity issue that requires executive alignment.

The window for advantageous CDMO partnerships is closing. Biopharma [innovators must rethink CDMO strategies](https://www.kbibiopharma.com/our-resources/biosecure-tariffs-and-the-new-cdmo-reality-for-biopharma-innovators) amid new tariffs and the BIOSECURE Act, focusing on long-term defensibility and supplier risk. Procurement teams that act decisively in Q1–Q2 2025 will secure better pricing, priority capacity, and regulatory certainty. Those that delay until after the OMB list is published will face constrained options and premium pricing that could persist for years.

## Sources

1. https://endpoints.news/insilico-bora-pharma-reveal-plans-for-ai-driven-manufacturing-company/
2. https://visionlifesciences.com/insights/biosecure-act-pharma-impact-2026
3. https://www.mofo.com/resources/insights/251218-biosecure-act-update
4. https://www.ijdra.com/index.php/journal/article/download/840/433
5. https://www.kbibiopharma.com/our-resources/biosecure-tariffs-and-the-new-cdmo-reality-for-biopharma-innovators
6. https://www.osborneclarke.com/insights/us-biosecure-act-your-supply-chain-risk
7. https://app.scientist.com/blog/2026/01/20/the-biosecure-act-navigating-changes-in-the-biopharma-supply-chain
8. https://www.outsourcedpharma.com/doc/biosecure-act-and-the-supply-chain-lessons-sponsors-can-t-ignore-0001

Source: https://cdmo.directory/posts/biosecure-act-cdmo-supply-chain-risk-5-10-annual-capacity-tightening-cdmo